Guigue Paul Adrien, Brezinov Yoav, Yasmeen Amber, Mbarik Maroua, Salvador Shannon, Lau Susie, Gotlieb Walter Henri, Brodeur Melica Nourmoussavi
Lady Davis Institute for Medical Research at the Jewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada.
Department of Experimental Surgery, McGill University, Montreal, QC H3T 1E2, Canada.
Cancers (Basel). 2024 Aug 14;16(16):2840. doi: 10.3390/cancers16162840.
Interleukin-10 (IL-10) has been shown to be present at high levels in the ascites of ovarian cancer (OC) patients; however, little is known about its prognostic value. We sought to correlate IL-10 levels in ascites and sera of OC patients with clinicopathologic characteristics and oncologic outcomes. IL-10 levels and clinical data from biobanked ascites and serum samples of OC patients were evaluated. Receiver operating characteristic curves were used to quantify marker performance and identify IL-10-high and IL-10-low groups. Correlations between IL-10 levels and clinicopathologic data were performed. Survival outcomes were calculated, while the factors affecting them were also investigated. A total of 106 patients had ascites samples, of which 44 serum samples were also available. Mean ascites IL-10 levels were significantly higher in patients with serous histology compared to endometrioid histology ( = 0.024). Fold-change in ascites IL-10 during treatment positively correlated with clinical response, as determined by a change in serum cancer antigen (CA)-125 levels ( = 0.0126). Median progression-free survival (PFS) and overall survival (OS) were shorter in patients with high compared with low ascites IL-10 levels (PFS: 18 versus 60 months; = 0.007, OS: 42 versus 85 months; = 0.029). A significant positive correlation was seen between ascites and sera IL-10 levels ( = 0.019). In multivariable analyses, a high ascites IL-10 level was associated with a significantly worse prognosis (PFS hazard ratio (HR) = 1.93; = 0.02). Patients with high ascites levels of IL-10 have worse outcomes, which are likely reflective of the immunosuppressive effect of IL-10. This highlights its potential role as an immunomodulator in the tumor microenvironment, leading to OC immune evasion.
白细胞介素 -10（IL-10）已被证实在卵巢癌（OC）患者的腹水中高水平存在；然而，其预后价值却知之甚少。我们试图将OC患者腹水中和血清中的IL-10水平与临床病理特征及肿瘤学结局相关联。对OC患者生物样本库中的腹水和血清样本的IL-10水平及临床数据进行了评估。采用受试者工作特征曲线来量化标志物性能，并确定IL-10高表达组和IL-10低表达组。分析了IL-10水平与临床病理数据之间的相关性。计算了生存结局，同时也研究了影响生存结局的因素。共有106例患者有腹水样本，其中44例也有血清样本。浆液性组织学患者的腹水IL-10平均水平显著高于子宫内膜样组织学患者（P = 0.024）。治疗期间腹水IL-10的变化倍数与临床反应呈正相关，临床反应通过血清癌抗原（CA）-125水平的变化来确定（P = 0.0126）。腹水IL-10水平高的患者与低水平患者相比，无进展生存期（PFS）和总生存期（OS）的中位数更短（PFS：18个月对60个月；P = 0.007，OS：42个月对85个月；P = 0.029）。腹水和血清IL-10水平之间存在显著正相关（P = 0.019）。在多变量分析中，腹水IL-10水平高与预后显著较差相关（PFS风险比（HR）= 1.93；P = 0.02）。腹水IL-10水平高的患者预后较差，这可能反映了IL-10的免疫抑制作用。这突出了其在肿瘤微环境中作为免疫调节剂的潜在作用，导致OC免疫逃逸。
